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Introduction {#cjp2138-sec-0001}
============

The cancer immune microenvironment has been intensively studied in the past few decades, paving the way for the recent clinical application of immunotherapies targeting immune checkpoints such as cytotoxic T‐lymphocyte associated protein 4 (CTLA4), programmed cell death 1 (PDCD1/PD1), and programmed cell death 1 ligand 1 (CD274/PDL1) [1](#cjp2138-bib-0001){ref-type="ref"}, [2](#cjp2138-bib-0002){ref-type="ref"}. Various immunogenomic approaches have been applied to dissect tumor‐immune cell interactions [3](#cjp2138-bib-0003){ref-type="ref"}, [4](#cjp2138-bib-0004){ref-type="ref"} and accumulating evidence supports the impact of host immunity on cancer progression and response to immunotherapy [4](#cjp2138-bib-0004){ref-type="ref"}, [5](#cjp2138-bib-0005){ref-type="ref"}, [6](#cjp2138-bib-0006){ref-type="ref"}, [7](#cjp2138-bib-0007){ref-type="ref"}, [8](#cjp2138-bib-0008){ref-type="ref"}. The latest report from the international ImmuneScore project showed that the ImmuneScore, which is derived from a digital immunohistochemistry measure of CD3^+^ and CD8^+^ lymphocytes in the tumor core and invasive margin, is a reliable prognostic biomarker in colon cancer [8](#cjp2138-bib-0008){ref-type="ref"}. Based on transcriptome data of bulk tissue samples, a number of computational tools attempting to enumerate infiltrating immune cells are emerging [9](#cjp2138-bib-0009){ref-type="ref"}. Recently, a novel gene signature‐based method called xCell was developed, identifying 64 immune and stromal cell types [10](#cjp2138-bib-0010){ref-type="ref"}. By integrating the advantages of gene set enrichment with deconvolution, xCell provides a comprehensive perspective on the cellular heterogeneity of tissues [10](#cjp2138-bib-0010){ref-type="ref"}, [11](#cjp2138-bib-0011){ref-type="ref"}.

In this complex cellular society, cytotoxic T cells (Tc) and NK cells are two main effector cell types that can attack tumor cells directly [12](#cjp2138-bib-0012){ref-type="ref"}. Upon exposure to transformed cells, they release perforin (a pore‐forming protein) and granzymes (a family of serine proteases) that will ultimately lead to target cell death [12](#cjp2138-bib-0012){ref-type="ref"}, [13](#cjp2138-bib-0013){ref-type="ref"}. Thus, local immune cytolytic activity can be quantified based on the transcript levels of perforin (*PRF1*) and granzyme A (*GZMA*) [14](#cjp2138-bib-0014){ref-type="ref"}. Using this method, it was reported that cytolytic activity varied substantially across cancer types, with higher cytolytic activity in tumor samples from kidney, stomach, head and neck, melanoma, ovary and glioma compared to the corresponding normal tissue samples. In contrast, cytolytic activity was lower in lung cancer and colorectal cancer samples than in the corresponding normal tissues [14](#cjp2138-bib-0014){ref-type="ref"}.

Squamous cell carcinoma of the oral tongue (SCCOT) is a subtype of squamous cell carcinoma of the head and neck (SCCHN) [15](#cjp2138-bib-0015){ref-type="ref"}, [16](#cjp2138-bib-0016){ref-type="ref"}. A high degree of tumor‐infiltrating lymphocytes and macrophages has been identified in SCCHN and infiltration of CD8^+^ T cells associates with good prognosis, whereas myeloid‐derived suppressor cells (MDSCs) and regulatory T cells (Tregs) associate with poor prognosis [4](#cjp2138-bib-0004){ref-type="ref"}, [5](#cjp2138-bib-0005){ref-type="ref"}. SCCHN represents a heterogeneous group of tumors arising from the squamous epithelium of the oral cavity, oropharynx, larynx, and hypopharynx. Despite being grouped as a single cancer type, distinct clinical, biological features and response to treatment have been seen between tumors from different subsites [16](#cjp2138-bib-0016){ref-type="ref"}, [17](#cjp2138-bib-0017){ref-type="ref"}, [18](#cjp2138-bib-0018){ref-type="ref"}, [19](#cjp2138-bib-0019){ref-type="ref"}. To characterize the immune microenvironment in SCCOT, the most common SCCHN subtype, we used transcriptome data analysis to estimate immune cell fractions and evaluated cytolytic activity according to mRNA levels of *GZMA* and *PFR1*. We show altered immune infiltration and increased cytolytic activity in tumor samples and in clinically tumor‐free tongue samples from patients with SCCOT compared to normal tongue from healthy individuals. Most importantly, we found that measures of cytolytic activity in tumor‐free samples confer prognostic information, whereas the same analysis of tumor samples does not.

Materials and methods {#cjp2138-sec-0002}
=====================

Patient material and ethical approval {#cjp2138-sec-0003}
-------------------------------------

This is a retrospective study of 31 patients with SCCOT. Tumor and tumor‐free samples (biopsies of clinically normal tongue tissue from the opposite side of the tongue) were collected from 21 patients. Only tumor tissue was available from eight patients, and from the remaining two patients only tumor‐free tissue could be collected for gene expression analysis. All tumor and tumor‐free samples were taken at the same time as the diagnostic biopsies, before treatment of the patients. Based on a standardized treatment protocol, when all examinations are ready, tumors are discussed at a multidisciplinary conference with participants from ENT, Oncology, Pathology, Radiology and Plastic Surgery, where treatment decisions are made. This conference should be within 18 days from arrival of the referral and therapy should start no longer than 12 days if surgical and 20 days if oncological after the conference. Patient characteristics are shown in Table [1](#cjp2138-tbl-0001){ref-type="table"}. Tissue biopsies had been consecutively collected and some patients were included in our previous studies with different objectives [20](#cjp2138-bib-0020){ref-type="ref"}, [21](#cjp2138-bib-0021){ref-type="ref"}, [22](#cjp2138-bib-0022){ref-type="ref"}, [23](#cjp2138-bib-0023){ref-type="ref"}, [24](#cjp2138-bib-0024){ref-type="ref"}. Biopsies taken from the lateral border of the tongue from 14 healthy volunteers not exposed to classic oral cancer risk factors (smoking and alcohol) had also been collected previously [20](#cjp2138-bib-0020){ref-type="ref"}. The size of tumor biopsies for mRNA analysis varied between patients, with a minimum of around 3 mm. The histology of the tumor samples was described on the adjacent diagnostic biopsies taken at the same time. All histopathological analyses have been performed by the same author (KN) who as an oral pathologist also does the clinical diagnostics on these cases. Due to the limited size of the tumor‐free and healthy control samples (3--4 mm) these were only judged clinically and no histological assessment was performed. The study was approved by the Regional Ethics Review Board, Umeå, Sweden (Dnr 03‐201 and Dnr 08‐003 M) and performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients and healthy individuals.

###### 

Clinicopathological data on patients with SCCOT

  No.     ID   Age   Sex      Sample[\*](#cjp2138-note-0003){ref-type="fn"}   Localization[†](#cjp2138-note-0004){ref-type="fn"}   TNM (clinical, 7th edition)   Stage   Treatment
  ----- ------ ----- -------- ----------------------------------------------- ---------------------------------------------------- ----------------------------- ------- -------------
  1      p40   80    Female   1                                               3                                                    T4N2bM0                       4       RT
  2      p42   68    Female   1                                               1                                                    T2N0M0                        2       RT, OP
  3      p14   77    Female   2                                               2                                                    T2N1M0                        2       RT, OP
  4      p24   64    Male     2                                               1                                                    T1N0M0                        1       OP
  5      p29   64    Female   2                                               2                                                    T2N0M0                        2       RT
  6      p68   62    Male     2                                               1                                                    T2N0M0                        2       OP, RT
  7      p70   71    Male     2                                               2                                                    T1N0M0                        1       OP, RT
  8      p82   19    Female   2                                               2                                                    T4N0M0                        4       RT, OP
  9      p83   64    Female   2                                               2                                                    T1N0M0                        1       OP
  10     p92   63    Female   2                                               2                                                    T2N0M0                        2       RT, OP, CYT
  11     p11   78    Male     3                                               2                                                    T2N0M0                        2       RT, OP
  12     p35   24    Female   3                                               1                                                    T2N0M0                        2       RT, OP
  13     p49   52    Female   3                                               3                                                    T4N2cM0                       4       RT
  14     p51   74    Male     3                                               1                                                    T2N0M0                        2       RT, OP
  15     p56   40    Female   3                                               3                                                    T2N2bM0                       3       RT, OP
  16     p58   61    Male     3                                               1                                                    T1N0M0                        1       OP
  17     p59   68    Female   3                                               1                                                    T2N0M0                        2       RT, OP
  18     p61   69    Male     3                                               3                                                    T4aN0M0                       4       RT
  19     p65   81    Female   3                                               3                                                    T2N0M0                        2       OP, RT
  20     p73   80    Male     3                                               3                                                    T4aN0M0                       4       RT
  21     p76   58    Male     3                                               3                                                    T4aN0M0                       4       RT
  22     p79   60    Male     3                                               2                                                    T1N0M0                        1       RT, OP
  23     p85   87    Female   3                                               1                                                    T2N0M0                        2       OP, RT
  24     p98   31    Male     3                                               3                                                    T2N0M0                        2       OP, RT
  25     p105  63    Male     3                                               2                                                    T1N0M0                        1       RT, OP
  26     p111  31    Female   3                                               2                                                    T1N0M0                        1       OP, RT
  27     p119  66    Male     3                                               2                                                    T2N0M0                        2       OP, RT
  28     p124  54    Male     3                                               3                                                    T4aN2bM0                      4       RT
  29     p131  74    Female   3                                               2                                                    T2N0M0                        2       OP, RT
  30     p137  71    Female   3                                               2                                                    T2N0M0                        2       RT, OP
  31     p138  50    Male     3                                               2                                                    T2N1M0                        2       RT, OP

CYT, cytostatics; OP, operation; RT, radiotherapy.

1 = only tumor‐free sample, 2 = only tumor sample, 3 = tumor‐free and tumor samples were collected.

1 = tongue, 2 = lateral border of the tongue, 3 = tongue with overgrowth outside the mobile tongue.

RNA isolation and gene expression profiling {#cjp2138-sec-0004}
-------------------------------------------

Biopsies were fresh‐frozen in liquid nitrogen and stored at −80 °C until RNA extraction. Procedures for RNA isolation and gene expression profiling for 18 tumors, 12 tumor‐free samples, and 14 healthy controls have been previously reported and raw data were deposited in ArrayExpress accession number E‐MTAB‐4678 [20](#cjp2138-bib-0020){ref-type="ref"}. For the rest of the samples, RNA isolation was performed using AllPrep DNA/RNA/miRNA Universal Kit (Qiagen, Hilden, Germany). Quantity and purity of RNA was measured using a NanoDrop ND‐1000 spectrophotometer (ThermoScientific, Wilmington, DE, USA). RNA quality was confirmed by Agilent RNA 6000 Nano kit (Agilent 2100 Bioanalyzer, Agilent Technologies, Santa Clara, CA, USA). As reported previously, 200 ng of total RNA was processed for gene expression profiling using Illumina HumanHT‐12 v4 Expression BeadChip (Illumina Inc., San Diego, CA, USA) [20](#cjp2138-bib-0020){ref-type="ref"}. Raw data were deposited in ArrayExpress and are available under accession number E‐MTAB‐5534. Microarray data normalization was performed using linear models and differential expression for microarray data (LIMMA) package [25](#cjp2138-bib-0025){ref-type="ref"}, the statistical language R and extension taken from Bioconductor.

Cell type estimation and cytolytic activity calculation {#cjp2138-sec-0005}
-------------------------------------------------------

We applied the xCell method [10](#cjp2138-bib-0010){ref-type="ref"} to study 34 immune cell types in a total of 66 samples (21 pairs of tumor/tumor‐free samples, 8 tumor samples, 2 tumor‐free samples, and 14 control samples). Although not described in the original publication [10](#cjp2138-bib-0010){ref-type="ref"}, xCell now also reports an ImmuneScore for each sample according to estimated levels of B cells, CD4^+^ T cells, CD8^+^ T cells, dendritic cells (DC), eosinophils, macrophages, monocytes, mast cells neutrophils, and NK cells (<https://github.com/dviraran/xCell/blob/master/R/xCell.R>). Granzyme A and perforin are two key cytolytic effectors that are specifically co‐expressed in cytotoxic lymphocytes [13](#cjp2138-bib-0013){ref-type="ref"}, [14](#cjp2138-bib-0014){ref-type="ref"}. To measure cytolytic activity in each sample according to the method of Rooney *et al* [14](#cjp2138-bib-0014){ref-type="ref"}, microarray probe intensity data for *GZMA* and *PRF1* were extracted and the geometric mean intensity of *GZMA* and *PRF1* calculated for each sample. After that, the mean intensity value was log‐transformed and presented as cytolytic activity score.

Confirmation of microarray data using RT‐qPCR {#cjp2138-sec-0006}
---------------------------------------------

Levels of *GZMA* and *PRF1* mRNAs were confirmed using RT‐qPCR in 12 healthy controls and in 12 matched pairs of tumor/tumor‐free samples. RevertAid H minus first strand cDNA synthesis kit (Fermentas, ThermoScientific, Wilmington, DE, USA) was used for cDNA synthesis and qPCR was performed using an IQ5 multicolor real‐time PCR detection system with IQ SYBR Green Supermix (Bio‐Rad Laboratories, Hercules, CA, USA). Primers used were *GZMA* (forward: ATGCTATGACCCAGCCACAC, reverse: GGTTTCACATCGTCCCCCTT), *PRF1* (forward: AAGACCCACCAGGACCAGTA, reverse: TCTTGAAGTCAGGGTGCAGC), *RPL13A* (reference gene, forward: GTACGCTGTGAAGGCATCAA, reverse: GTTGGTGTTCATCCGCTTG). Primers for another reference gene *GAPDH* were ordered from Primerdesign Ltd (Southampton, UK). The primer sequences were not provided by the company.

Statistics {#cjp2138-sec-0007}
----------

Cell type composition and cytolytic activity were compared between different sample groups using nonparametric Mann--Whitney *U* test, and Spearman correlation coefficient (rho) was calculated to evaluate correlation strength. Comparisons between clinicopathological variables and cytolytic activity (low versus high) were determined by Fisher\'s exact test. The Kaplan--Meier method with log‐rank test was used to compare survival curves between groups. Cut‐off score for patient classification into high or low groups was chosen when showing the most significant difference. For multivariate Cox regression analysis, we considered patient age at diagnosis and TNM staging as covariates. All statistical tests were conducted in IBM SPSS Statistics 25 (IBM Corp., Armonk, NY, USA). A two‐sided *P* value \<0.05 was considered significant.

Results {#cjp2138-sec-0008}
=======

Cell type enumeration {#cjp2138-sec-0009}
---------------------

Gene expression profiling data on 14 healthy controls, 23 tumor‐free and 29 tumor samples were uploaded to the xCell webtool. When comparing tumor to tumor‐free samples, there were significant alterations in all types of assessed immune cells (*p* \< 0.05), except NKT cells, CD8^+^ T cells, naive B cells and plasma cells. When comparing tumor‐free samples to healthy controls, significant alterations in nine immune cell types were also seen (*p* \< 0.05, Figure [1](#cjp2138-fig-0001){ref-type="fig"}A). The most significantly elevated immune cell types in tumor‐free samples were DC, followed by CD8^+^ effector memory T cells (Tem), activated DC (aDC), NK cells, CD8^+^ central memory T cells (Tcm), conventional DC (cDC) and CD8^+^ T cells. Monocytes and basophils were significantly decreased in tumor‐free samples compared to healthy controls. The xCell calculated ImmuneScore increased from control to tumor‐free to tumor samples (Figure [1](#cjp2138-fig-0001){ref-type="fig"}B). The ImmuneScores of all tumor and tumor‐free samples are shown in Table [2](#cjp2138-tbl-0002){ref-type="table"}.

![Immune features in tumor and clinically tumor‐free tongue samples from SCCOT patients compared to control tongue from healthy individuals. (A) Box‐plots of immune cell types according to xCell enumeration scores in tumor‐free samples compared to healthy controls (*p* \< 0.05). Changes in the tumor samples are also shown. Small circles indicate outliers and asterisks indicate extreme outliers. (B) xCell‐derived ImmuneScores (*p* \< 0.05 tumor‐free samples versus healthy control; *p* \< 0.001 tumor‐free versus tumor). (C) Cytolytic activity (*p* \< 0.001 tumor‐free versus healthy controls; *p* \< 0.001 tumor‐free versus tumor).](CJP2-5-240-g001){#cjp2138-fig-0001}

###### 

xCell ImmuneScore and cytolytic activity score for all samples

  ID     Status   Follow‐up month   Time to recurrence (month)   xCell ImmuneScore   Cytolytic activity score          
  ------ -------- ----------------- ---------------------------- ------------------- -------------------------- ------ ------
  p40    DWD      1                                              0.52                                           6.02   
  p42    DWD      9                 7                            0.16                                           5.14   
  p14    ADF      177                                                                0.59                              6.03
  p24    ADF      168                                                                0.74                              6.98
  p29    DWD      29                20                                               0.52                              7.40
  p68    DOD      9                 6                                                0.44                              7.16
  p70    ADF      109                                                                0.52                              7.01
  p82    DOD      18                12                                               0.60                              7.12
  p83    ADF      93                                                                 0.70                              8.58
  p92    DOD      20                6                                                0.73                              7.54
  p11    DWD      3                                              0.34                0.56                       5.54   5.99
  p35    DOD      13                10                           0.14                0.03                       4.85   4.97
  p49    DWD      3                                              0.16                0.54                       5.29   7.16
  p51    ADF      132                                            0.26                0.45                       5.37   5.95
  p56    DOD      16                12                           0.78                0.17                       8.26   5.67
  p58    ADF      119                                            0.24                0.42                       5.58   6.00
  p59    DOD      7                                              0.20                0.40                       5.14   5.07
  p61    DDF      81                                             0.22                0.54                       5.45   6.59
  p65    ADF      112                                            0.16                0.71                       5.40   7.59
  p73    DOD      19                11                           0.24                0.58                       5.13   6.45
  p76    ADF      103                                            0.25                0.52                       5.49   5.92
  p79    ADF      108                                            0.34                0.51                       5.67   6.52
  p85    DOD      2                 2                            0.31                0.57                       5.54   7.88
  p98    ADF      60                                             0.21                0.75                       4.66   6.50
  p105   ADF      55                                             0.42                0.48                       5.96   6.91
  p111   ADF      51                                             0.19                0.26                       5.27   5.40
  p119   ADF      45                                             0.25                0.66                       5.38   6.68
  p124   DOD      3                                              0.15                0.55                       5.14   5.95
  p131   ADF      38                                             0.24                0.24                       5.42   4.91
  p137   ADF      36                                             0.10                0.56                       5.34   7.02
  p138   ADF      35                                             0.23                0.31                       5.85   5.43

ADF, alive disease free; DDF, dead disease free; DOD, dead of disease; DWD, dead with disease.

Cytolytic activity {#cjp2138-sec-0010}
------------------

According to our microarray data, a strong correlation between *GZMA* and *PRF1* mRNA levels was seen (Spearman correlation coefficient rho = 0.839, *p* \< 0.001). Next, we calculated cytolytic activity in all 66 samples according to *GZMA* and *PRF1* levels (Table [2](#cjp2138-tbl-0002){ref-type="table"}). Significant alterations were found not only between tumor and tumor‐free samples (*p* \< 0.001), but also between tumor‐free and control samples (*p* \< 0.001). Similar to the ImmuneScore, a steady increase in cytolytic activity was seen from healthy control to tumor‐free to tumor samples (Figure [1](#cjp2138-fig-0001){ref-type="fig"}C). Spearman\'s correlation showed that ImmuneScore and cytolytic activity were significantly correlated (rho = 0.857, *p* \< 0.001). Correlations between cytolytic activity and infiltration of a subset of immune cells were also identified. The top three correlated immune cell types were CD8^+^ Tem (rho = 0.903, *p* \< 0.001), NK cells (rho = 0.842, *p* \< 0.001) and activated DC (rho = 0.827, *p* \< 0.001), reinforcing the reliability of cytolytic activity calculation based on *GZMA* and *PRF1* mRNA levels. To confirm the microarray data, *GZMA* and *PRF1* mRNA levels were measured using RT‐qPCR in 12 healthy controls and 12 pairs of tumor‐free and tumor samples. A significant correlation between microarray and RT‐qPCR results was seen (*GZMA*, rho = 0.897, *p* \< 0.001; *PRF1*, rho = 0.691, *p* \< 0.001).

Immune features and prognosis {#cjp2138-sec-0011}
-----------------------------

As tumor‐related immune features have been shown to be prognostic across several tumor types, we investigated the effect of immune infiltration on SCCOT prognosis. Overall survival was defined as the time from date of completion of first‐line treatment to death, and disease free survival as the time from date of completion of first‐line treatment to date of first recurrence or of death without recurrence. Patients were divided into high or low score groups according to immune cell composition, ImmuneScore or cytolytic activity in their tumor samples. Kaplan--Meier analysis showed no significant difference in clinical outcome of patients with high or low scores (Figure [2](#cjp2138-fig-0002){ref-type="fig"}A,B). Next, we divided patients into high or low score groups according to immune cell composition, ImmuneScore or cytolytic activity in their tumor‐free samples. Cytolytic activity correlated with patient survival, whereas there were no associations with immune cell composition or ImmuneScore. As shown in Figure [2](#cjp2138-fig-0002){ref-type="fig"}C, patients with high cytolytic activity in their tumor‐free tissue (*n* = 15) had improved overall survival compared to patients with low cytolytic activity in their tumor‐free samples (*n* = 8, *p* = 0.046). A correlation between cytolytic activity and disease‐free survival was also seen (*p* = 0.040, Figure [2](#cjp2138-fig-0002){ref-type="fig"}D). There was no significant difference in age, sex, tumor size and stage between high or low score groups (Table [3](#cjp2138-tbl-0003){ref-type="table"}); however, within the survival data for high cytolytic activity patients, we found that the three patients who had died within 3 months were all 78 years or older (patient numbers 1, 11, and 23). In subsequent multivariate Cox regression analysis adjusted for tumor stage and patient age, cytolytic activity in tumor‐free samples remained an independent prognostic factor for disease‐free survival (hazard ratio = 4.20, 95% CI = 1.09--16.20, *p* = 0.037).

![The influence of cytolytic activity in tumor and tumor‐free samples on patient survival. Kaplan--Meier curves of overall (A,C) and disease‐free (B,D) survival are shown. Blue lines represent patients with high cytolytic activity and red lines patients with low cytolytic activity. (A,B) Tumor samples (C,D) Tumor‐free samples.](CJP2-5-240-g002){#cjp2138-fig-0002}

###### 

Associations between clinicopathological variables and cytolytic activity

  Variable                       Low cytolytic activity in tumor‐free samples (*n* = 8)   High cytolytic activity in tumor‐free samples (*n* = 15)  *P* value
  ----------------------------- -------------------------------------------------------- ---------------------------------------------------------- --------------------------------
  Age (years, mean)                                        51                                                        67                             0.057 (Mann--Whitney *U* test)
  Sex (female/male)                                       5/3                                                       6/9                             0.400 (Fisher\'s exact test)
  Tumor size (1,2/4)                                      5/3                                                       12/3                            0.621 (Fisher\'s exact test)
  Tumor Stage (I, II/III, IV)                             5/3                                                       10/5                            1.000 (Fisher\'s exact test)

Discussion {#cjp2138-sec-0012}
==========

Multiple studies have shown that infiltration of immune cells into the tumor microenvironment is a prognostic factor in cancer. Recent studies focusing on tumor immune cytolytic activity also demonstrated that transcript levels of two key cytolytic effectors, *GZMA* and *PRF1*, correlate with patient survival [14](#cjp2138-bib-0014){ref-type="ref"}, [26](#cjp2138-bib-0026){ref-type="ref"}. In this study, using transcriptome profiling data, we estimated immune cell composition and cytolytic activity in SCCOT, clinically tumor‐free tongue tissue from SCCOT patients and control tongue tissue from healthy individuals. Correlations between immune infiltration, cytolytic activity and patient survival were also investigated. As expected, significantly altered immune cell composition was seen in tumors compared to tumor‐free samples. However, we also found elevated infiltration of DC, CD8^+^ T cells and NK cells in tumor‐free tongue compared to control samples from healthy individuals, whereas infiltration of monocytes and basophils showed a decrease within the tumor‐free samples. The overall ImmuneScore was also higher in tumor‐free samples compared to healthy controls. Importantly, we also found increased cytolytic activity in tumor‐free samples compared to healthy controls. Therefore, similar to a recent report that several immune cell types are highly enriched in normal tissue adjacent to tumor compared with healthy tissue in eight different tissue types (bladder, breast, colon, liver, lung, prostate, thyroid, and uterus) [11](#cjp2138-bib-0011){ref-type="ref"}, we demonstrate the presence of an expanded field of immunoreactivity in clinically tumor‐free tongue tissue in SCCOT patients. It should be noted that unlike other sites within the head and neck region, such as oropharynx and nasopharynx, there appears to be no role for viral infections (either human papillomavirus or Epstein--Barr virus) in SCCOT [23](#cjp2138-bib-0023){ref-type="ref"}, [24](#cjp2138-bib-0024){ref-type="ref"}. Thus, viral influences are unlikely to account for any variations in the immunoreactivity.

We also found that patients with high cytolytic activity in tumor‐free tongue had improved survival compared with patients with low cytolytic activity. Cytolytic activity in tumors has been shown to correlate with mutation load and number of predicted neoantigens [14](#cjp2138-bib-0014){ref-type="ref"}, [26](#cjp2138-bib-0026){ref-type="ref"}. Oral SCC, including SCCOT, is a paradigm of Slaughter\'s concept of 'field cancerization' [27](#cjp2138-bib-0027){ref-type="ref"}, in which tumors are thought to arise from an expanded pool of genetically altered pre‐neoplastic cells [28](#cjp2138-bib-0028){ref-type="ref"}, [29](#cjp2138-bib-0029){ref-type="ref"}. This concept has been modified to include exposure of the tissue microenvironment to damaging/mutagenic agents, termed 'etiologic field effects' [30](#cjp2138-bib-0030){ref-type="ref"}, [31](#cjp2138-bib-0031){ref-type="ref"}. The recently identified changes in gene expression profiles in clinically tumor‐free tongue in patients with SCCOT compared to healthy controls provide definitive evidence for field effects in this disease [20](#cjp2138-bib-0020){ref-type="ref"}. Therefore, SCCOT patients with high cytolytic activity in the tumor‐free parts of the tongue could be indicative of immunogenicity to cells with high mutation burden in the cancer field and/or immune responses due to etiologic field effects. It has been reported that overall gene expression profiles of histologically normal oral mucosa are useful in identifying markers for clinical outcome and recurrence in patients with oral SCC [32](#cjp2138-bib-0032){ref-type="ref"}, [33](#cjp2138-bib-0033){ref-type="ref"}. Here, we found that cytolytic activity in the tumor‐free tongue in patients with SCCOT provides prognostic information. In contrast, levels of immune infiltration or degree of cytolytic activity within the tumor is not predictive for patient survival. Thus, measuring cytolytic activity in tumor‐free samples contralateral to the tumor could be an effective approach for evaluating prognosis in patients with SCCOT.

Unlike 'ImmuneScore', a methodology based on immunohistochemistry and derived from the density and location of two lymphocyte populations [7](#cjp2138-bib-0007){ref-type="ref"}, the xCell reported an 'ImmuneScore' derived from estimated levels of B cells, CD4^+^, and CD8^+^ T cells, DC, eosinophils, macrophages, monocytes, mast cells, neutrophils and NK cells. As the functional plasticity of immune cells is not fully understood and information on cell location is lacking, the value of bulk gene expression data based 'ImmuneScore' in clinical practice is limited.

There are two potential limitations to our study. First, the number of samples analyzed is relatively small, due to the difficulties in obtaining sufficient control and tumor‐free samples. Second, sample size excludes the ability for immunohistochemical confirmation of the data. Nonetheless, our novel analyses provide a useful approach to investigate immune activity in clinical samples and identify significant associations with patient prognosis for further investigation.

In conclusion, elevated cytolytic activity was seen in tumor‐free tissue from SCCOT patients, where it was found to be an independent prognostic factor for disease‐free survival. Whilst the reason(s) for this association are at present unclear, integrating immunogenomic data from tumor‐free and tumor samples to characterize the immune microenvironment in SCCOT could help predict clinical outcome for patients with SCCOT.
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